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not prescribed DAPT.
CONCLUSIONS While the majority of TAVR patients in the U.S.
receive DAPT therapy at hospital discharge, antiplatelet prescribing
patterns varied signiﬁcantly among US TAVR hospitals. Outcomes for
DAPT treated patients were generally better than those not treated
with DAPT, but further studies are needed to deﬁne the best antith-
rombotic medical treatment following TAVR.
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BACKGROUND Transcatheter aortic valve replacement (TAVR) has
been established as alternative treatment for inoperable or high-risk
patients with symptomatic severe aortic stenosis. However, TAVR for
bicuspid aortic valve stenosis has been still relatively contraindicated
and the clinical data of TAVR for bicuspid aortic valve has been
limited. We sought to evaluate the clinical outcomes of TAVR for
bicuspid aortic valve.
METHODS The Bicuspid TAVR registry was conducted in 9 centers
from 7 countries in Asia, Europe and North America between March
2006 and February 2015. Baseline demographics, procedural and
echocardiographic data were prospectively collected from each center
and a joint database was created.
RESULTS One hundred and thirty-one patients were included. Mean
age was 77.2  9.4 years and 33.6% were female. Medtronic CoreValve,
Edwards SAPIEN/XT and SAPIEN 3 were used in 48.9%, 43.5% and
5.3% of patients, respectively. Approaches were either transarterial
(transfemoral, 78.6%; subclavian, 1.5%; direct aortic, 13.0%) or trans-
apical (6.1%). Mean logistic European System for Cardiac Operative
Risk Evaluation (EuroSCORE) and Society of Thoracic Surgeons (STS)
score were 16.2  12.5 and 5.3  5.1, respectively. At 30 days, the
incidence of all stroke, major vascular complications, life-threateningbleeding, and acute kidney injury (stage 2 or 3) were 1.6%, 4.6%, 4.6%
and 3.8%, respectively. Paravalvular regurgitation moderate or
greater occurred 6.3% in overall, 8.6% in CoreValve, 4.3% in SAPIEN/
XT and 0.0% in SAPIEN 3. Rates of death at 30 days and 1 year were
4.1% and 12.7% for overall, 7.0% and 16.6% for SAPIEN/XT, and 1.6%
and 10.1% for CoreValve, respectively. In multivariate analysis, age
(hazard ratio, 1.17; 95% conﬁdence interval: 1.01 – 1.35; p ¼ 0.038) and
creatinine (hazard ratio, 1.74; 95% conﬁdence interval: 1.05 – 2.89;
p ¼ 0.03) were independent predictors of all-cause death.
Clinical Outcomes of TAVR for Bicuspid Aortic Valve StenosisOverall
(N [ 121)SAPIEN/XT
(N [ 57)CoreValve
(N [ 64) p valueMortality at 30
days5 (4.1%) 4 (7.0%) 1 (1.6%) 0.19Mortality at 1
year14 (12.7%) 8 (16.6%) 6 (10.1%) 0.31All stroke 2 (1.7%) 1 (1.8%) 1 (1.6%) 0.99Life-threatening
bleeding6 (5.0%) 2 (3.5%) 4 (6.3%) 0.68Acute kidney
injury stage 2
to 35 (4.1%) 4 (7.0%) 1 (1.6%) 0.19Major vascular
complication5 (4.1%) 5 (8.8%) 0 (0.0%) 0.02Aortic
regurgitation
moderate or
greater7 (6.7%) 2 (4.3%) 5 (8.6%) 0.08Device success 111 (91.7%) 53 (93.0%) 58 (90.6%) 0.75Safety endpoint
at 30 days98 (81.0%) 42 (73.7%) 56 (87.5%) 0.065CONCLUSIONS This registry reﬂects the real-life experience of TAVR
for bicuspid aortic valve stenosis.
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BACKGROUND Experience with transcatheter aortic valve implanta-
tion (TAVI) for severe aortic regurgitation is limited due to the risk of
insufﬁcient anchoring of the valve stent within the non-calciﬁed
aortic annulus. The aim of this study is to report the initial experience
